Glanbia Plc · EURONEXT:GL9
Glanbia — Q3 2024 Earnings Presentation
8 slides from Glanbia's earnings presentation, Nov 6, 2024
Slide 1: Q3 2024 Interim Management Statement
Q3 2024 Interim Management Statement 6 November 2024 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
Important Notice This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both economic and busi
Slide 3: YTD Q3 2024 – Highlights
YTD Q3 2024 – Highlights • YTD Q3 Group performance in line with expectations • Optimum Nutrition & Isopure performance continued with strong volume growth • Volume trends in NS continue to improve with strong growth in premix and protein solutions businesses • Announcing a change in operating model
Slide 4: GPN – YTD Q3 Performance
GPN – YTD Q3 Performance Revenue growth* +1.7% Volume +3.2% Price (4.0%) Performance Healthy Nutrition Lifestyle 53rd Week +2.5% • Revenue growth* broadly in line with prior period in Americas and +4.7% in International % of GPN Revenue 65% 18% • Volume momentum continued with strong volume growth p
Slide 5: NS – YTD Q3 2024 Performance
NS – YTD Q3 2024 Performance Revenue growth* +14.4% Volume +5.0% Price (0.9%) 53rd week +3.1% Acquisitions / Disposals +7.2% • Volume growth driven predominantly by premix and protein solutions businesses • Pricing declines were driven by lower dairy market pricing and reduced input costs in the fir
Slide 6: Strategic Updates
Strategic Updates New operating model being implemented in 2025, supported by Group wide transformation to position the Group for the next phase of growth Rationale Revised group structure • Health & Nutrition segment focused on higher growth and higher margin solutions • Dairy Nutrition segment wit
Slide 7: Financing & Capital Allocation; Reiterating 2024 Guidance
Financing & Capital Allocation Reiterating 2024 Guidance Adjusted EPS growth* 5% – 8% Net debt $620m Total committed facilities of $1.3bn Revenue GPN revenue growth*: 2% – 5% growth NS volume growth: 3% – 5% FY24 capex expected to be $80m – $90m Earnings GPN EBITDA margin: 16.0% – 16.5% growth FY24
Slide 8: Q&A
Q&A A performance driven purpose led global nutrition company 8 || Glanbia plc Q3 2024 IMS Presentation